CSIMarket Company Name, Ticker, Competitors, else..
 
Korro Bio Inc   (NASDAQ: KRRO)
 
Price: $10.3043 $0.32 3.250%
Day's High: $10.584199905395508 Week Perf: -25.49 %
Day's Low: $ 10.02 30 Day Perf: -21.82 %
Volume (M): 79,330 52 Wk High: $ 55.89
Volume (M$): $ 0 52 Wk Avg: $15.58
Open: $10.08 52 Wk Low: $5.20



 Market Capitalization (Millions $) 182
 Shares Outstanding (Millions) 18
 Employees 58
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -107
 Cash Flow (TTM) (Millions $) 28
 Capital Exp. (TTM) (Millions $) 0

Business Description


Korro Bio, Inc. is a biotechnology company focused on researching and developing oligonucleotide-based therapeutic candidates, including programs targeting alpha-1 antitrypsin deficiency (AATD). The company advances its development candidates through preclinical studies and clinical trials and plans to submit regulatory applications. Korro Bio also collaborates with partners such as Novo Nordisk A/S.


   Company Address: 60 First Street Cambridge 2141 MA
   Company Phone Number: 468-1999   Stock Exchange / Ticker: NASDAQ KRRO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110...

Published Thu, Nov 21 2024 12:30 PM UTC

Breakthrough in Alpha-1 Antitrypsin Deficiency: Korro s KRRO-110 Receives Green Light for Clinical TrialsIn an exciting development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), Korro Bio has announced that it has received both Australian Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance to initiate its Phase 1/2a ...
Clinical Study

Korro Bio Announces Key Regulatory Milestone and Financial Performance Amidst Strategic Development Initiatives

Published Mon, Nov 4 2024 12:25 PM UTC

: Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company dedicated to the advancement of innovative genetic medicines for a range of rare and common diseases, has recently marked significant milestones in its strategic roadmap. The company has announced the submission of a regulatory filing for a Phase 1/2 clinical study of KRRO-110, targeting Alpha-1 Antitrypsin Defici...
Partnership

Emerging Innovations in Gene Therapy Korro Bio’s Strategic Collaboration with Novo Nordisk

Published Mon, Sep 16 2024 12:01 PM UTC

In a recent announcement, Korro Bio has forged a strategic partnership with pharmaceutical giant Novo Nordisk, focusing on the development of two therapeutic candidates aimed at addressing cardiometabolic diseases. This collaboration is set to leverage Korro Bio s proprietary OPERA™ platform, which specializes in oligonucleotide-directed RNA editing. In this article, we wi...
Stock Market Announcement

Korro Bio Secures Spot in Coveted Russell Indexes, Paving the Way for Genetic Medicine Advancements

Published Mon, Jul 1 2024 12:00 PM UTC

Korro Bio Joins Prestigious Russell Indexes, Amplifying Its Potential
CAMBRIDGE, Mass., July 01, 2024 - Korro Bio, Inc. (Nasdaq: KRRO), an innovative biopharmaceutical company specializing in developing groundbreaking genetic medicines through RNA editing, has garnered significant recognition by being included in the illustrious Russell 2000, Russell 3000, and Russell M...
Clinical Study

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

Published Mon, May 20 2024 6:30 PM UTC

A Promising Frontier: Preclinical Advances of KRRO-110 for Alpha-1 Antitrypsin Deficiency Korro Bio, Inc., a notable name in the burgeoning field of RNA editing technologies, has recently presented compelling preclinical data on its lead development candidate, KRRO-110, at the American Thoracic Society 2024 International Conference. This article will delve into the specific...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 76.22
Price to Sales (Expected) -
Price to Book 1.76
PEG (TTM) -

Financial Strength Current
Quick Ratio 12.89
Working Capital Ratio 13.34
Leverage Ratio (MRQ) 0.58
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -10.01 $
Revenues (TTM) 0.14 $
Cash Flow (TTM) 1.59 $
Cash 9.24 $
Book Value 5.86 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,838,690
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.